Alessandro Pileri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2886216/publications.pdf

Version: 2024-02-01

306	10,275	44069	40979
papers	citations	48 h-index	93 g-index

315	315	315	6140
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estimating the incidence of COVIDâ€19 skin manifestations on the general population in a territorial setting. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
2	Prognostic significance of Bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	1
3	Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management. Presse Medicale, 2022, 51, 104109.	1.9	8
4	Mycosis fungoides involving the genital area. Italian Journal of Dermatology and Venereology, 2022, 156, .	0.2	1
5	Who is the culprit? A toxic epidermal necrolysis case in a patient treated with rituximab plus polatuzumab. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
6	A case of pityriasis lichenoides et varioliformis acuta developed after first dose of <scp>Oxfordâ€“AstraZeneca COVID</scp>â€19 vaccine. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
7	<scp>BCL</scp>â€2 expression in primary cutaneous follicle center lymphoma is associated with a higher risk of cutaneous relapses: A study of 126 cases. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
8	TOX Expression in Mycosis Fungoides and Sezary Syndrome. Diagnostics, 2022, 12, 1582.	2.6	2
9	Is Dermoscopy Useful for the Diagnosis of Pseudolymphomas?. Dermatology, 2021, 237, 213-216.	2.1	4
10	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÃ©zary Syndrome. Journal of Investigative Dermatology, 2021, 141, 484-495.	0.7	31
11	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). JDDG - Journal of the German Society of Dermatology, 2021, 19, 99-102.	0.8	2
12	Bullous Wells Syndrome: a needle in the haystack. International Journal of Dermatology, 2021, 60, e150-e153.	1.0	0
13	Red dyeâ€related tattoo reactions: Could optical coherence tomography be of help?. Skin Research and Technology, 2021, 27, 469-471.	1.6	0
14	A pink nodule on the left subscapular region in an 8â€yearâ€old girl. JDDG - Journal of the German Society of Dermatology, 2021, 19, 620-622.	0.8	0
15	Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 961-968.	2.8	5
16	Italian expertâ€based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an eâ€Delphi consensus. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 334-342.	1.5	4
17	Chilblain lesions after COVIDâ€19 mRNA vaccine. British Journal of Dermatology, 2021, 185, e3.	1.5	20
18	Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports, 2021, 11, 10555.	3.3	3

#	Article	IF	Citations
19	Inâ€depth, singleâ€centre, analysis of changes in emergency service access after the spread of COVIDâ€19 across Italy. Clinical and Experimental Dermatology, 2021, 46, 1588-1589.	1.3	1
20	Dimethyl fumarate: a case of improvement of alcoholic steatohepatitis in an elderly psoriatic patient. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	1
21	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Frontiers in Oncology, 2021, 11, 733770.	2.8	13
22	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 4680.	3.7	6
23	Erythroderma: psoriasis or lymphoma? A diagnostic challenge and therapeutic pitfall. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	2
24	Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis?. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.2	1
25	The Microenvironmentâ€™s Role in Mycosis Fungoides and SÃ©zary Syndrome: From Progression to Therapeutic Implications. Cells, 2021, 10, 2780.	4.1	17
26	Iatrogenic Kaposi sarcoma during tumor necrosis factor alpha inhibitors. Italian Journal of Dermatology and Venereology, 2021, 156, 113-114.	0.2	0
27	Pityriasis lichenoides triggered by measlesâ€mumpsâ€rubella vaccine injection. JDDG - Journal of the German Society of Dermatology, 2020, 18, 758-760.	0.8	7
28	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. Hematological Oncology, 2020, 38, 831-833.	1.7	1
29	Cutaneous adverseâ€events in patients treated with Ibrutinib. Dermatologic Therapy, 2020, 33, e14190.	1.7	7
30	Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. American Journal of Clinical Dermatology, 2020, 21, 833-854.	6.7	25
31	BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role. Frontiers in Oncology, 2020, 10, 662.	2.8	8
32	Herpes zoster in COVIDâ€19â€positive patients. International Journal of Dermatology, 2020, 59, 1028-1029.	1.0	93
33	Changes in emergency service access after spread of COVIDâ€19 across Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e350-e351.	2.4	19
34	Granulomatous tattoo reaction in a nivolumab-treated patient. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 530-532.	0.8	1
35	Merkel cell carcinoma: a prompt diagnosis to increase survival. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e478-e480.	2.4	0
36	Asymptomatische brÃunliche LÃsionen an Armen und Beinen. JDDG - Journal of the German Society of Dermatology, 2019, 17, 659-662.	0.8	0

#	Article	IF	Citations
37	Brownish asymptomatic lesions on the arms and legs. JDDG - Journal of the German Society of Dermatology, 2019, 17, 659-662.	0.8	1
38	Bexarotene as maintenance treatment after therapies other than skinâ€directed therapy in advancedâ€stage mycosis fungoides: a pilot study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e367-e369.	2.4	5
39	Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers, 2019, 11, 595.	3.7	70
40	New therapies and old sideâ€effects in mycosis fungoides treatment: brentuximab vedotinâ€induced alopecia. British Journal of Dermatology, 2019, 180, 1535-1536.	1.5	6
41	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica, 2019, 104, 729-737.	3.5	58
42	Primary cutaneous B-cell lymphoma: narrative review of the literature. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 466-479.	0.8	6
43	Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukemia patients. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 605-606.	0.8	3
44	SÃ©zary Syndrome without erythroderma featuring a CD30+ progression. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 494-495.	0.8	0
45	Verrucous mycosis fungoides. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 504-505.	0.8	1
46	Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. Italian Journal of Dermatology and Venereology, 2019, , .	0.2	0
47	Primary cutaneous CD8+ CD30+ lymphoproliferative disorder in a patient with acquired CD4 immunodeficiency. Italian Journal of Dermatology and Venereology, 2019, , .	0.2	0
48	Primary cutaneous peripheral Tâ€cell lymphoma not otherwise specified a rare and aggressive lymphoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e373-e376.	2.4	5
49	Primary cutaneous small/mediumâ€sized pleomorphic Tâ€cell lymphoproliferative disorder shows a common vascular pattern at dermoscopy. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e318-e321.	2.4	8
50	A large mass and erythematousâ€violaceous plaques. JDDG - Journal of the German Society of Dermatology, 2018, 16, 372-375.	0.8	0
51	The role of myeloid derived suppressor cells in mycosis fungoides. Cancer Immunology, Immunotherapy, 2018, 67, 1175-1176.	4.2	2
52	Plaques and tumors in a patient with refractory SÃ©zary syndrome treated with mogamulizumab. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1265.	0.8	3
53	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370.	1.2	89
54	Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktÃrem SÃ©zary-Syndrom. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1266.	0.8	1

#	Article	IF	Citations
55	An Asymptomatic Plaque on the Chest: A Quiz. Acta Dermato-Venereologica, 2018, 98, 294-296.	1.3	0
56	ErythematÃ¶se Plaques und Tumoren im Gesicht und an den Armen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1162-1165.	0.8	0
57	Erythematous plaques and tumors on the face and arms. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1162-1164.	0.8	0
58	Ein groÃŸer Tumor und lividâ€erythematÃ¶se Plaques. JDDG - Journal of the German Society of Dermatology, 2018, 16, 372-375.	0.8	0
59	Dermatofibrosarcoma protuberans secondary to a decorative tattoo: An Isotattootopic Response?. Indian Journal of Dermatology, 2018, 63, 439.	0.3	4
60	Alopecia areata-like mycosis fungoides: lions for lambs. Italian Journal of Dermatology and Venereology, 2018, 153, 293-295.	0.2	2
61	Squamous cell carcinoma developed after ingenol mebutate therapy: a possible consequence of the treatment?. Italian Journal of Dermatology and Venereology, 2018, 153, 442-443.	0.2	1
62	Idiopathic follicular mucinosis: can dermoscopy be helpful?. Italian Journal of Dermatology and Venereology, 2018, 153, 440-441.	0.2	0
63	Extramedullary metastatic plasmacytoma in multiple myeloma. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 741-743.	0.8	0
64	Leukemia cutis in a Ph+ ALL patient treated with ponatinib. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 730-731.	0.8	0
65	Maintenance phase in psoralen-ultraviolet A phototherapy of early-stage mycosis fungoides. AÂcritically appraised topic. British Journal of Dermatology, 2017, 177, 406-410.	1.5	14
66	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. Molecular Cancer Research, 2017, 15, 541-552.	3.4	24
67	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and SÃ©zary syndrome?. European Journal of Dermatology, 2017, 27, 49-53.	0.6	8
68	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 575-582.	2.8	20
69	Photodynamic therapy: An option in mycosis fungoides. Photodiagnosis and Photodynamic Therapy, 2017, 20, 107-110.	2.6	12
70	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	1.2	98
71	Erosive pustular dermatosis of the leg: an uncommon entity?. Italian Journal of Dermatology and Venereology, 2017, 152, 675-678.	0.2	3
72	Vemurafenib mucosal sideâ€effect. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1053-1055.	2.4	6

#	Article	IF	Citations
73	Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 715-718.	4.9	28
74	Erythematous induration of the chest. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1291-1293.	0.8	1
75	ErythematÃ¶se Induration im Brustbereich. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1291-1293.	0.8	0
76	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	1.6	328
77	Vascular endothelial growth factor A (<scp>VEGFA</scp>) expression in mycosis fungoides. Histopathology, 2015, 66, 173-181.	2.9	14
78	Bosentan and Extracorporeal Photochemotherapy in Eosinophilic Fasciitis. International Journal of Lower Extremity Wounds, 2014, 13, 160-161.	1.1	6
79	Large granular lymphocytic leukaemia mimicking ulcer of the lower limb. International Wound Journal, 2014, 11, 104-105.	2.9	1
80	Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia, 2014, 28, 1606-1616.	7.2	164
81	Annular lesions located on the right forearm. Indian Journal of Dermatology, 2014, 59, 636.	0.3	0
82	Multiple familial trichodiscomas. Cutis, 2014, 93, E6-7.	0.3	1
83	Chilblain lupus erythematosus in a patient affected by <scp>H</scp>odgkin lymphoma. Australasian Journal of Dermatology, 2013, 54, 74-75.	0.7	0
84	Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. Immunotherapy, 2013, 5, 427-433.	2.0	34
85	Persistent Agmination of Lymphomatoid Papulosis: An Ongoing Debate. Dermatology, 2012, 225, 131-134.	2.1	8
86	Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution. Pediatric Blood and Cancer, 2012, 58, 306-306.	1.5	12
87	Mycosis fungoides: disease evolution of the "lion queen" revisited. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 523-31.	0.8	12
88	Combination treatment in CTCL: the current role of bexarotene. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 573-80.	0.8	5
89	Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 603-8.	0.8	18
90	Lymphoma classification: the quiet after the storm. Seminars in Diagnostic Pathology, 2011, 28, 113-123.	1.5	20

#	Article	IF	Citations
91	Primary cutaneous lymphomas: a reprisal. Seminars in Diagnostic Pathology, 2011, 28, 214-233.	1.5	17
92	Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS). European Journal of Dermatology, 2011, 21, 624-625.	0.6	9
93	Syringotropic Mycosis Fungoides. American Journal of Surgical Pathology, 2011, 35, 100-109.	3.7	59
94	Atypical piloleiomyoma of the face presenting with central ulceration. Dermatology Reports, 2011, 3, e50.	0.8	5
95	Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Localized on the Dorsum. Case Reports in Dermatology, 2009, 1, 87-92.	0.8	3
96	Tattoo-associated Pseudolymphomatous Reaction and its Successful Treatment with Hydroxychloroquine. Acta Dermato-Venereologica, 2009, 89, 327-328.	1.3	24
97	Defective interleukin-2 induction of lymphokine-activatedkiller (LAK) activity in peripheral blood T lymphocytesof patients with monoclonal gammopathies. Clinical and Experimental Immunology, 2008, 79, 100-104.	2.6	23
98	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. Journal of Clinical Oncology, 2008, 26, 3166-3175.	1.6	68
99	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood, 2008, 111, 4004-4013.	1.4	243
100	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia, 2007, 21, 340-350.	7.2	571
101	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. Journal of Clinical Oncology, 2006, 24, 1376-1382.	1.6	199
102	Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. Histopathology, 2005, 47, 645-646.	2.9	3
103	The karma of Kikuchi's disease. Clinical Immunology, 2005, 114, 27-29.	3.2	17
104	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. Journal of Clinical Oncology, 2004, 22, 1460-1468.	1.6	116
105	Indolent lymphoma: the pathologistâ€™s viewpoint. Annals of Oncology, 2004, 15, 12-18.	1.2	17
106	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.	7.2	63
107	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer, 2003, 97, 2748-2759.	4.1	71
108	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. Cancer, 2003, 98, 983-992.	4.1	18

#	Article	IF	Citations
109	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplantation, 2003, 31, 767-773.	2.4	15
110	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. Journal of Clinical Oncology, 2003, 21, 1398-1403.	1.6	35
111	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, 99, 75-82.	1.4	147
112	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2002, 100, 1559-1565.	1.4	89
113	Real-time polymerase chain reaction in multiple myeloma. Experimental Hematology, 2002, 30, 529-536.	0.4	24
114	Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma. Annals of Hematology, 2002, 81, 448-453.	1.8	20
115	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. British Journal of Haematology, 2002, 117, 642-645.	2.5	11
116	High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplantation, 2002, 30, 725-732.	2.4	47
117	Hodgkin's lymphoma: the pathologist's viewpoint. Journal of Clinical Pathology, 2002, 55, 162-176.	2.0	189
118	Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting. Leukemia and Lymphoma, 2001, 40, 679-682.	1.3	6
119	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 2001, 113, 1051-1059.	2.5	48
120	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia, 2001, 15, 256-263.	7.2	28
121	Growth advantage of chronic myeloid leukemia CFU-GM in vitro : survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoidsâ€‰Â±â€‰Î±-interferon. Leukemia, 2001, 15, 422-429.	7.2	7
122	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia, 2001, 15, 1941-1949.	7.2	49
123	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Experimental Hematology, 2001, 29, 183-193.	0.4	64
124	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. British Journal of Haematology, 2000, 109, 46-53.	2.5	16
125	Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplantation, 2000, 26, 1185-1191.	2.4	59
126	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia, 2000, 14, 740-747.	7.2	35

#	Article	IF	Citations
127	Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplantation, 2000, 25, 25-29.	2.4	24
128	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Medical Oncology, 2000, 17, 203-210.	2.5	27
129	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96, 864-869.	1.4	201
130	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96, 864-869.	1.4	1
131	Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 1999, 17, 208-208.	1.6	222
132	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. Blood, 1999, 94, 1248-1253.	1.4	152
133	Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients. Stem Cells, 1999, 17, 55-61.	3.2	26
134	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia, 1999, 13, 1456-1462.	7.2	37
135	Clinical relevance of minimal residual disease monitoring in non-Hodgkinâ€™s lymphomas: a critical reappraisal of molecular strategies. Leukemia, 1999, 13, 1691-1695.	7.2	42
136	Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Hematology, 1999, 78, 539-543.	1.8	97
137	Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF: opposing effects observed with different cytotoxic drugs and time exposure. Leukemia Research, 1999, 23, 931-938.	0.8	4
138	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	127
139	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	2
140	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. Blood, 1999, 94, 1248-1253.	1.4	1
141	A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. Bone Marrow Transplantation, 1998, 21, 409-413.	2.4	11
142	G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplantation, 1998, 21, 401-407.	2.4	55
143	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplantation, 1998, 22, 449-455.	2.4	48
144	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 1998, 28, 127-134.	1.0	48

#	Article	IF	Citations
145	The Italian Experience on Interferon as Maintenance Treatment in Multiple Myeloma: Ten Years After. Blood, 1998, 92, 2184-2186.	1.4	14
146	High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. New England Journal of Medicine, 1997, 336, 1290-1298.	27.0	460
147	DIAGNOSIS, PROGNOSIS, AND STANDARD TREATMENT OF MULTIPLE MYELOMA. Hematology/Oncology Clinics of North America, 1997, 11, 111-131.	2.2	67
148	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. Blood, 1997, 89, 724-491.	1.4	158
149	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia, 1997, 11, 1793-1798.	7.2	99
150	Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplantation, 1997, 19, 23-29.	2.4	15
151	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. Bone Marrow Transplantation, 1997, 20, 341-343.	2.4	7
152	Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: Modulating effects of dihydroxylated vitamin D3, Î± interferon and â€˜stem cell factorâ€™. Leukemia Research, 1997, 21, 51-58.	0.8	8
153	DISTRIBUTION OF Tâ€CELL SIGNALLING MOLECULES IN HUMAN MYELOMA. British Journal of Haematology, 1997, 97, 810-814.	2.5	100
154	Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. British Journal of Haematology, 1997, 99, 41-46.	2.5	15
155	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. British Journal of Haematology, 1997, 99, 685-691.	2.5	16
156	Conventional induction treatments do not influence overall survival in multiple myeloma. British Journal of Haematology, 1997, 96, 333-337.	2.5	17
157	Use of Modified Functional Assays for Activated Protein C Resistance in Patients with Basally Prolonged aPTT. Thrombosis and Haemostasis, 1997, 78, 1042-1048.	3.4	5
158	Procoagulant Activity of Mononuclear Cells Is Increased in Myeloproliferative and Myelodysplastic Diseases. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 157-163.	0.3	1
159	Combined differentiating therapy for myelodysplastic syndromes: A phase II study. Leukemia Research, 1996, 20, 867-876.	0.8	34
160	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. British Journal of Haematology, 1996, 94, 376-378.	2.5	28
161	Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2. Leukemia and Lymphoma, 1996, 21, 325-330.	1.3	7
162	Oncogenes in the Pathogenesis of Multiple Myeloma. , 1996, , 169-172.		0

#	Article	IF	Citations
163	Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. British Journal of Haematology, 1995, 91, 535-543.	2.5	24
164	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+cells. British Journal of Haematology, 1995, 90, 625-632.	2.5	9
165	Retinoic acid inhibits the growth of human myeloma cells in vitro. British Journal of Haematology, 1995, 89, 555-560.	2.5	15
166	1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Best Practice and Research: Clinical Haematology, 1995, 8, 705-719.	1.1	24
167	Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. European Journal of Immunology, 1995, 25, 1306-1311.	2.9	40
168	Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood, 1995, 85, 3679-3687.	1.4	66
169	High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood, 1995, 85, 1596-1602.	1.4	133
170	Interferon-Î³ in Multiple Myeloma. Leukemia and Lymphoma, 1995, 18, 215-219.	1.3	13
171	Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Annals of Oncology, 1995, 6, S3-S8.	1.2	17
172	T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?. Leukemia and Lymphoma, 1995, 17, 63-70.	1.3	6
173	Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplantation, 1995, 16, 223-8.	2.4	23
174	High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.. Journal of Clinical Oncology, 1994, 12, 503-509.	1.6	72
175	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. Leukemia and Lymphoma, 1994, 15, 17-20.	1.3	28
176	Recombinant interferon-Î³ inhibits the in vitro proliferation of human myeloma cells. British Journal of Haematology, 1994, 86, 726-732.	2.5	27
177	Correlation between disease activity and T-cell CD3 chain expression in a B-cell lymphoma. British Journal of Haematology, 1994, 88, 886-888.	2.5	33
178	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. British Journal of Haematology, 1994, 87, 494-502.	2.5	5
179	Molecular characteristics of human plasma, platelet and vascular cell PAI-1. Comparison between normal and thrombocytemic subjects. Fibrinolysis, 1994, 8, 28-30.	0.5	2
180	Recombinant interferon-Î³ in a patient with multiple myeloma. European Journal of Cancer, 1994, 30, 1731.	2.8	1

#	Article	IF	Citations
181	Classification of patients affected by multiple myeloma using a neural network software. European Journal of Haematology, 1994, 52, 182-183.	2.2	9
182	Selection and characterization of early hematopoietic progenitors using an anti-CD71/S06 immunotoxin. Experimental Hematology, 1994, 22, 166-73.	0.4	5
183	THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. British Journal of Haematology, 1993, 83, 672-673.	2.5	3
184	Microalbuminuria in insulin-dependent diabetes is associated with high levels of prothrombin fragment 1+2. Thrombosis Research, 1993, 72, 541-546.	1.7	9
185	Fibrinolytic Imbalance in Essential Thrombocythemia: Role of Platelets. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 38-44.	0.3	3
186	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-2713.	1.4	116
187	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood, 1993, 82, 1787-1797.	1.4	35
188	Interferon plus Glucocorticoids as Intensified Maintenance Therapy Prolongs Tumor Control in Relapsed Myeloma. Acta Haematologica, 1993, 90, 71-76.	1.4	13
189	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.. Journal of Experimental Medicine, 1993, 178, 1091-1096.	8.5	109
190	Multiple myeloma: â€˜earlyâ€™ plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. British Journal of Haematology, 1993, 85, 504-513.	2.5	29
191	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-2713.	1.4	2
192	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood, 1993, 82, 1787-1797.	1.4	0
193	Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]. Blood, 1993, 82, 3507-3508.	1.4	2
194	Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplantation, 1993, 11, 271-7.	2.4	34
195	Co-stimulatory signal delivered by CD73 molecule to human CD45RAhiCD45ROlo (naive) CD8+ T lymphocytes. Journal of Immunology, 1993, 151, 3961-70.	0.8	36
196	Lupus Anticoagulant: Interference withIn VivoProstaglandin Production and with Platelet Sensitivity to Prostacyclin. Scandinavian Journal of Rheumatology, 1992, 21, 124-128.	1.1	6
197	Manipulating Hemopoietic Progenitors: the Role of High-Dose Chemotherapy and Granulocyte Colony Stimulating Factor. Leukemia and Lymphoma, 1992, 7, 31-31.	1.3	0
198	Cyclosporin A and dipyridamole: An effective combination against the generationa of cytotoxic T lymphocytes (CTL). Pharmacological Research, 1992, 26, 12-13.	7.1	0

#	Article	IF	Citations
199	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.. Journal of Clinical Oncology, 1992, 10, 1955-1962.	1.6	48
200	Standard Chemotherapy for Myelomatosis: An Area of Great Controversy. Hematology/Oncology Clinics of North America, 1992, 6, 371-382.	2.2	21
201	C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 1992, 80, 733-737.	1.4	265
202	Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture. Leukemia Research, 1992, 16, 743-750.	0.8	2
203	Multiple independent immunoglobulin classâ€switch recombinations occurring within the same clone in myeloma. British Journal of Haematology, 1992, 82, 676-680.	2.5	13
204	Isoform-specific associations of CD45 with accessory molecules in human T lymphocytes. European Journal of Immunology, 1992, 22, 365-371.	2.9	89
205	Multiple myeloma: Intensified maintenance therapy with recombinant interferonâ€Î±â€2b plus glucocorticoids. European Journal of Haematology, 1992, 49, 93-97.	2.2	9
206	Sequential administration of OKT3 (antiâ€CD3) and interleukinâ€2 in two patients with chemoresistant hematological disease. European Journal of Haematology, 1992, 49, 150-152.	2.2	3
207	C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 1992, 80, 733-737.	1.4	2
208	Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction [letter; comment]. Blood, 1992, 79, 291-292.	1.4	3
209	Maintenance Treatment with Recombinant Interferon Alfa-2b Prolongs Remission and Survival in Patients with Multiple Myeloma Responding to Induction Chemotherapy. , 1992, , 67-72.		0
210	Self-renewal inhibition of acute myeloid leukemia clonogenic cells by biological inducers of differentiation. Leukemia, 1992, 6, 100-6.	7.2	20
211	Human recombinant stem cell factor stimulates in vitro proliferation of acute myeloid leukemia cells and expands the clonogenic cell pool. Leukemia, 1992, 6, 642-8.	7.2	16
212	Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. European Journal of Cancer & Clinical Oncology, 1991, 27, 22-27.	0.7	63
213	Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments]. Blood, 1991, 78, 1770-1780.	1.4	43
214	Dipyridamole in vitro suppresses the generation of Tâ€cell cytotoxic functions: Synergistic activity with cyclosporine. European Journal of Haematology, 1991, 46, 6-10.	2.2	2
215	Dual rearrangement of immunoglobulin and Tâ€cell receptor gene in a case of Tâ€cell hairyâ€cell leukemia. European Journal of Haematology, 1991, 46, 71-76.	2.2	6
216	Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. European Journal of Haematology, 1991, 47, 305-309.	2.2	17

#	Article	IF	Citations
217	Amplification of T Cell Activation Induced by CD73 (Ecto-5â€²Nucleotidase) Engagement. Advances in Experimental Medicine and Biology, 1991, 309B, 155-158.	1.6	6
218	Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood, 1990, 76, 1375-1379.	1.4	66
219	Complete remission in multiple myeloma. Lancet, The, 1990, 335, 52-53.	13.7	5
220	Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy. New England Journal of Medicine, 1990, 322, 1430-1434.	27.0	374
221	Alphaâ€2b recombinant interferon (Intronâ€A) as maintenance treatment in multiple myeloma. European Journal of Haematology, 1990, 45, 9-11.	2.2	0
222	Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplantation, 1990, 6, 143-5.	2.4	42
223	Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood, 1990, 76, 1375-9.	1.4	11
224	Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. Cancer Research, 1990, 50, 6478-82.	0.9	25
225	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. Acta Haematologica, 1989, 82, 122-125.	1.4	18
226	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. Tumori, 1989, 75, 1-3.	1.1	4
227	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. Journal of Clinical Oncology, 1989, 7, 119-125.	1.6	72
228	Effect of two aliphatic aldehydes, methylglyoxal and 4-hydroxypentenal, on the growth of Yoshida ascites hepatoma AH-130. Chemico-Biological Interactions, 1989, 70, 227-240.	4.0	16
229	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. European Journal of Immunology, 1989, 19, 1037-1044.	2.9	46
230	MACOP-B treatment for advanced stage diffuse large cell lymphoma: A multicenter Italian study. European Journal of Cancer & Clinical Oncology, 1989, 25, 1441-1449.	0.7	18
231	Paraproteinaemias and platelet aggregation: Role of whole blood aggregometry. Thrombosis Research, 1989, 55, 267-277.	1.7	5
232	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION. Lancet, The, 1989, 334, 580-585.	13.7	676
233	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. European Journal of Haematology, 1989, 43, 30-34.	2.2	2
234	Granulocyte-macrophage colony-stimulating factor requires interaction with accessory cells or granulocyte-colony stimulating factor for full stimulation of human myeloid progenitors. Blood, 1989, 73, 402-405.	1.4	1

#	Article	IF	Citations
235	Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treatment Reviews, 1988, 15, 43-48.	7.7	43
236	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	48
237	Human myeloma: Several subsets of circulating lymphocytes express plasma cellâ€associated antigens. European Journal of Haematology, 1988, 40, 299-304.	2.2	28
238	Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. European Journal of Haematology, 1988, 41, 334-340.	2.2	5
239	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	44
240	Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clinical and Experimental Immunology, 1988, 73, 214-8.	2.6	30
241	The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5'nucleotidase activity. Journal of Immunology, 1988, 141, 3768-75.	0.8	15
242	Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5'nucleotidase deficiency. Journal of Clinical & Laboratory Immunology, 1988, 26, 89-95.	0.1	5
243	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-8.	1.4	8
244	Absence of (â^')[3H]desmethoxyverapamil binding sites on human platelets and lack of evidence for voltage-dependent calcium channels. European Journal of Pharmacology, 1987, 142, 83-91.	3.5	13
245	Cytobiological Studies in Multiple Myeloma. Acta Haematologica, 1987, 78, 41-42.	1.4	2
246	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. Acta Haematologica, 1987, 78, 239-242.	1.4	17
247	Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. Leukemia Research, 1987, 11, 265-272.	0.8	14
248	Immunologic and virologic findings in hemophiliacs do not correlate with ectoâ€5â€²nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual men. European Journal of Haematology, 1987, 38, 310-314.	2.2	2
249	Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. Clinical and Experimental Immunology, 1987, 69, 426-32.	2.6	14
250	Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. Alabama Journal of Medical Sciences, 1987, 24, 400-4.	0.1	1
251	Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. Haematologica, 1987, 72, 171-5.	3.5	13
252	Cell kinetics of multiple myeloma. Hematologic Pathology, 1987, 1, 137-42.	0.2	3

#	Article	IF	Citations
253	Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody. Tumori, 1986, 72, 135-137.	1.1	16
254	Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes. Journal of Immunology, 1986, 137, 484-9.	0.8	21
255	Reactive Plasmacytosis. Acta Haematologica, 1985, 73, 108-110.	1.4	20
256	Treatment of multiple myeloma: A randomized study of three different regimens. Leukemia Research, 1985, 9, 1043-1049.	0.8	20
257	Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.. Journal of Clinical Oncology, 1985, 3, 1503-1507.	1.6	8
258	Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood, 1985, 65, 530-534.	1.4	11
259	Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. British Journal of Haematology, 1984, 58, 689-696.	2.5	91
260	Mixed lymphocyte reaction in human monoclonal gammopathies. Experientia, 1983, 39, 1137-1139.	1.2	0
261	Kinetics of circulating B lymphocytes in human myeloma. Blood, 1983, 61, 812-814.	1.4	35
262	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. Clinical and Experimental Immunology, 1983, 51, 173-7.	2.6	23
263	Kinetics of circulating B lymphocytes in human myeloma. Blood, 1983, 61, 812-4.	1.4	2
264	Human Myeloma: Kinetics of the Remission Phase. Acta Haematologica, 1982, 68, 237-240.	1.4	15
265	Idiotypic lymphocytes in human monoclonal gammopathies. Annales De L'Institut Pasteur Immunologie, 1981, 132, 9-19.	0.8	22
266	Monitoring of a Long Survival Myeloma Patient. Tumori, 1981, 67, 571-573.	1.1	6
267	Early B lymphocytes in man. Experientia, 1980, 36, 1124-1125.	1.2	3
268	Hairy-Cell Leukemia. New England Journal of Medicine, 1977, 296, 881-882.	27.0	14
269	B lymphocytes receptors: a new biological approach for immunofluorescence studies. Haematologica, 1977, 62, 221-2.	3.5	2
270	Early recruitment in the human myeloma cell population after cytostatic treatment. Haematologica, 1976, 61, 184-93.	3.5	8

#	Article	IF	Citations
271	Letter: Alkylating agents and myeloma cells. Blood, 1976, 47, 1056-1057.	1.4	3
272	Myeloid Cell Actinomycin Binding in Human Myeloid Leukaemia. Acta Haematologica, 1974, 51, 1-8.	1.4	1
273	Feulgen hydrolysis of normal and leukemic blood cells. European Journal of Cancer, 1974, 10, 563-566.	0.9	0
274	Actinomycin binding and uridine incorporation by human normal bone marrow cells. Experientia, 1974, 30, 951-952.	1.2	5
275	In vivo kinetic studies in human myeloma. Haematologica, 1974, 59, 10-24.	3.5	17
276	Actinomycin Binding Capacity in Human Leukaemic Lymphoid Cells. Acta Haematologica, 1972, 48, 89-97.	1.4	10
277	Bone Marrow Return and Division of Circulating Acute Lymphoblastic Leukaemia Cells. Acta Haematologica, 1972, 47, 277-282.	1.4	5
278	Lymphocyte actinomycin binding capacity in chronic lymphocytic leukaemia. Experientia, 1972, 28, 1484-1484.	1.2	3
279	The problem of anaemia in the acute leukaemias. European Journal of Cancer, 1970, 6, 33-38.	0.9	9
280	Proliferative Potential of Out-of-cycle Leukaemic Cells. Nature, 1969, 224, 375-376.	27.8	71
281	Unusual blast proliferation and kinetics in acute lymphoblastic leukaemia. European Journal of Cancer, 1969, 5, 343-348.	0.9	6
282	Changes in protein metabolism in proliferating and non-proliferating human acute leukaemia cells treated with actinomycin-D. Experientia, 1969, 25, 862-863.	1.2	1
283	Different Blast Kinetics in Acute Myeloblastic and Lymphoblastic Leukaemia. Acta Haematologica, 1969, 41, 215-224.	1.4	11
284	Degradation of rapidly labelled RNA in proliferating and non-proliferating human acute leukemia cells. Experientia, 1968, 24, 1267-1268.	1.2	3
285	UNRESPONSIVENESS TO PHYTO-HÃ†MAGGLUTININ OF ACUTE LYMPHOBLASTIC LEUKÃ†MIA CELLS. Lancet, The, 1968, 292, 409-410.	13.7	0
286	Characteristics of Cell Proliferation in Children's Lymphoblastic Leukemia. Tumori, 1968, 54, 147-160.	1.1	1
287	Proliferative Activity of the Cells of Acute Leukaemia in Relapse and in Steady State. Acta Haematologica, 1967, 38, 193-199.	1.4	24
288	Presence of Three Philadelphia Chromosomes (Ph1) in the Blastic Crisis of a Case of Chronic Myeloid Leukemia. Tumori, 1967, 53, 315-321.	1.1	5

#	Article	IF	Citations
289	Proliferation Kinetics of Acute Leukemia Cells in Relation to the Chemotherapy. Acta Geneticae Medicae Et Gemellologiae, 1967, 17, 30-39.	0.1	1
290	Non-self-maintaining Kinetics of Proliferating Blasts in Human Acute Leukaemia. Nature, 1967, 216, 188-189.	27.8	48
291	Cell population kinetics in human acute leukaemia. European Journal of Cancer, 1967, 3, 301-307.	0.9	47
292	Degradation of RNA and changes in protein metabolism in human acute leukaemia cells treated with actinomycin D. Revue FranÃ§aise D'Â©tudes Cliniques Et Biologiques, 1967, 12, 986-90.	0.1	1
293	Cytogenetical and proliferative characteristics of acute promyelocytic leukaemia cells. European Journal of Cancer, 1966, 2, 189-192.	0.9	2
294	Â«In Vivo Â» Studies on RNA Metabolism of Human Acute Leukemia Cells.. Tumori, 1965, 51, 419-431.	1.1	1
295	X-RAYS AND PHILADELPHIA CHROMOSOME. Lancet, The, 1965, 285, 1336-1337.	13.7	10
296	Proliferation and Maturation Defect in Acute LeukÃ¦mia Cells. Nature, 1964, 203, 92-94.	27.8	115
297	In vivo Incorporation of Tritiated Thymidine in Acute LeukÃ¦mia Chromosomes. Nature, 1963, 200, 807-809.	27.8	16
298	Proliferative Capacity of Acute LeukÃ¦mia Cells. Nature, 1960, 187, 611-612.	27.8	58
299	Radioautographic Investigations on DNA and Protein Metabolism in 2 Cases of Di Guglielmoâ€™s Disease. Blood, 1960, 16, 1122-1132.	1.4	21
300	Nucleic Acids and Protein Metabolism in Acute Leukemia Cells. Blood, 1960, 16, 1555-1563.	1.4	47
301	Interrelationship between RNA and protein metabolism in human normal bone marrow cells. Experimental Cell Research, 1960, 20, 645-646.	2.6	4
302	Incorporation of Thymidine labelled with Tritium by Circulating Cells of Infectious Mononucleosis. Nature, 1959, 183, 1691-1692.	27.8	33
303	The effect of administration of 6-mercaptopurine on nucleic acids and alkaline phosphatase of regenerating rat liver. Cancer, 1958, 11, 222-225.	4.1	13
304	Increased transaminase activity in the liver after administration of cortisone. Biochimica Et Biophysica Acta, 1957, 24, 250-254.	1.3	77
305	The effect of cortisone on the glucose-6-phosphatase activity in normal and regenerating rat liver. Clinica Chimica Acta, 1957, 2, 280-283.	1.1	1
306	Biochimica Dei Tessuti Iperplastici: Modificazioni Del Metabolismo Cellulare Indotte Dalla Rigenerazione Epatica. Tumori, 1957, 43, 137-165.	1.1	0